Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics has commenced trading on the U.S. OTCQB Venture Market, enhancing its engagement with U.S. investors and expanding its presence in the U.S. market. This move coincides with the company’s AMPLICITY clinical trial for advanced pancreatic cancer opening at five sites in the U.S., and is part of Amplia’s broader strategy to educate investors about its FAK inhibitor program, which includes the promising drug narmafotinib.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also significant in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 2,681,963
Technical Sentiment Signal: Sell
Current Market Cap: A$64.13M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.